New England Private Wealth Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $297K | Hold |
1,975
| – | – | 0.03% | 178 |
|
|
2026
Q1 | $252K | Hold |
1,975
| – | – | 0.03% | 173 |
|
|
2025
Q4 | $241K | Buy |
+1,975
| New | +$226K | 0.03% | 163 |
|
|
2025
Q3 | – | Sell |
-3,948
| Closed | -$340K | – | 180 |
|
|
2025
Q2 | $340K | Sell |
3,948
-209
| -5% | -$16.7K | 0.05% | 127 |
|
|
2025
Q1 | $337K | Hold |
4,157
| – | – | 0.05% | 112 |
|
|
2024
Q4 | $374K | Hold |
4,157
| – | – | 0.06% | 109 |
|
|
2024
Q3 | $411K | Hold |
4,157
| – | – | 0.07% | 104 |
|
|
2024
Q2 | $385K | Sell |
4,157
-1,000
| -19% | -$89.7K | 0.07% | 102 |
|
|
2024
Q1 | $506K | Buy |
5,157
+1,209
| +31% | +$112K | 0.09% | 92 |
|
|
2023
Q4 | $352K | Hold |
3,948
| – | – | 0.07% | 103 |
|
|
2023
Q3 | $288K | Buy |
3,948
+1
| +0% | +$80 | 0.06% | 100 |
|
|
2023
Q2 | $328K | Sell |
3,947
-809
| -17% | -$67.7K | 0.07% | 91 |
|
|
2023
Q1 | $362K | Hold |
4,756
| – | – | 0.07% | 83 |
|
|
2022
Q4 | $395K | Hold |
4,756
| – | – | 0.08% | 78 |
|
|
2022
Q3 | $377K | Hold |
4,756
| – | – | 0.09% | 77 |
|
|
2022
Q2 | $427K | Hold |
4,756
| – | – | 0.08% | 80 |
|
|
2022
Q1 | $427K | Hold |
4,756
| – | – | 0.08% | 80 |
|
|
2021
Q4 | $532K | Hold |
4,756
| – | – | 0.09% | 76 |
|
|
2021
Q3 | $598K | Hold |
4,756
| – | – | 0.11% | 66 |
|
|
2021
Q2 | $644K | Hold |
4,756
| – | – | 0.12% | 65 |
|
|
2021
Q1 | $645K | Hold |
4,756
| – | – | 0.11% | 65 |
|
|
2020
Q4 | $670K | Hold |
4,756
| – | – | 0.15% | 59 |
|
|
2020
Q3 | $530K | Hold |
4,756
| – | – | 0.13% | 59 |
|
|
2020
Q2 | $532K | Hold |
4,756
| – | – | 0.15% | 57 |
|
|
2020
Q1 | $368K | Hold |
4,756
| – | – | 0.13% | 61 |
|
|
2019
Q4 | $452K | Hold |
4,756
| – | – | 0.12% | 59 |
|
|
2019
Q3 | $363K | Sell |
4,756
-450
| -9% | -$37.4K | 0.09% | 107 |
|
|
2019
Q2 | $456K | Sell |
5,206
-1,000
| -16% | -$85.3K | 0.11% | 98 |
|
|
2019
Q1 | $563K | Buy |
6,206
+1,000
| +19% | +$85.1K | 0.15% | 84 |
|
|
2018
Q4 | $373K | Hold |
5,206
| – | – | 0.11% | 96 |
|
|
2018
Q3 | $499K | Sell |
5,206
-1,000
| -16% | -$97K | 0.13% | 89 |
|
|
2018
Q2 | $591K | Buy |
6,206
+1,000
| +19% | +$91.9K | 0.17% | 81 |
|
|
2018
Q1 | $456K | Buy |
5,206
+453
| +10% | +$41.4K | 0.13% | 93 |
|
|
2017
Q4 | $403K | Buy |
4,753
+2
| +0% | +$168 | 0.11% | 95 |
|
|
2017
Q3 | $411K | Buy |
4,751
+2
| +0% | +$160 | 0.12% | 88 |
|
|
2017
Q2 | $367K | Buy |
4,749
+7
| +0.1% | +$496 | 0.11% | 95 |
|
|
2017
Q1 | $329K | Buy |
4,742
+1
| +0% | +$67 | 0.11% | 97 |
|
|
2016
Q4 | $281K | Buy |
4,741
+1
| +0% | +$62 | 0.1% | 98 |
|
|
2016
Q3 | $314K | Buy |
4,740
+2
| +0% | +$124 | 0.11% | 91 |
|
|
2016
Q2 | $256K | Sell |
4,738
-1,066
| -18% | -$58.4K | 0.1% | 98 |
|
|
2016
Q1 | $300K | Sell |
5,804
-3,443
| -37% | -$179K | 0.12% | 88 |
|
|
2015
Q4 | $649K | Sell |
9,247
-990
| -10% | -$67.5K | 0.26% | 57 |
|
|
2015
Q3 | $638K | Sell |
10,237
-2,915
| -22% | -$230K | 0.27% | 53 |
|
|
2015
Q2 | $1.11M | Buy |
13,152
+9,243
| +236% | +$719K | 0.42% | 44 |
|
|
2015
Q1 | $288K | Buy |
+3,909
| New | +$273K | 0.11% | 78 |
|
Other funds holding XBI
JFG
New England Private Wealth Advisors's XBI Position: Q2 2026 in Review
New England Private Wealth Advisors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 1,975 shares worth $297K. The position accounts for 0.03% of the portfolio, ranked #178.
New England Private Wealth Advisors first reported a position in XBI in Q1 2015 and has held it in 45 quarters since. The position peaked at $1.11M in Q2 2015. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.
- New England Private Wealth Advisors held 1,975 shares of State Street SPDR S&P Biotech ETF worth $297K as of Q2 2026.
- New England Private Wealth Advisors left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
- State Street SPDR S&P Biotech ETF made up 0.03% of New England Private Wealth Advisors's portfolio in Q2 2026, its #178 holding.
- New England Private Wealth Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and has held it in 45 quarters since.
- New England Private Wealth Advisors's State Street SPDR S&P Biotech ETF position peaked at $1.11M in Q2 2015.
- 932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.
Based on New England Private Wealth Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.